Professional Documents
Culture Documents
TO WATCH
IN 2020
Investing in individual companies isn’t right for everyone. Our shares to watch are for people who understand the risks of investing in
equities. It’s higher-risk as your investment is dependent on the fate of that company – if a company fails you risk losing your whole
investment. Investors should make sure they understand the companies they’re investing in, the company specific risks, and make
sure any businesses they own are held as part of a diversified portfolio.
In a world where high growth companies think they have the resilience to weather
are richly valued and economic growth turbulence in the long run.
NICHOLAS HYETT looks uncertain we think it pays to focus
Equity Analyst on profitable, cash generative businesses. This factsheet isn’t personal advice. If
you’re not sure if an investment is right for
It means there’s a bit more cyclicality in you please seek advice. All investments
the mix than usual – companies that are fall as well as rise in value so you could get
more closely tied to the wider economy. back less than you invest. Yield figures are
We’ve put more emphasis on dividends
WPP, Ibstock and DS Smith are all more variable and not guaranteed. They should
than in previous years, with three of the five
exposed here, and their share prices could not be seen as a reliable indicator of
companies having prospective yields above
suffer if conditions turn sour. However, we future income.
the market average. That’s no accident.
IMPORTANT NOTES:
This factsheet is not personal advice or a recommendation to buy, sell or hold any investment. If investors are not sure of the suitability
of an investment for their circumstances, they should seek advice. No view is given on the present or future value or price of any
investment, and investors should form their own view on any proposed investment. Unless otherwise stated estimates, including
prospective yields, are a consensus of analyst forecasts provided by Thomson Reuters.
These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Past performance is not a
guide to the future and investments rise and fall in value so investors could make a loss.
This factsheet has not been prepared in accordance with legal requirements designed to promote the independence of investment
research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead
of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential
conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.
Information correct as at 25 November 2019 unless otherwise stated. This publication is issued by Hargreaves Lansdown Asset
Management Ltd, One College Square South, Anchor Road, Bristol BS1 5HL who are authorised and regulated by the Financial
Conduct Authority.
*2018 reflects disposal proceeds received, e = forecast estimate. Source: Refinitiv Eikon, 25/11/19
DS SMITH
The whole package
40
35
30
25
20
15
10
0
2020e
2021e
2022e
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
140 45
Novo Nordisk was one of the first
40
industrial producers of insulin. And 90 120
years later treating diabetes remains its 35
100 30
core business. The group supplies nearly
half of all insulin worldwide, and sales of 80 25
the hormone (which controls blood sugar) 60 20
accounted for 53% of sales last year. 15
40
Diabetes is a chronic rather than acute 10
illness, and sufferers generally use insulin 20 5
for their entire lives. Given the variation - 0
between different types of insulin, lots
2001
2011
2020e
2000
2006
2013
2008
2009
2015
2004
2012
2018
2005
2010
2002
2021e
2003
2016
2007
2014
2017
2019e
1999
of patients tend to stick with a particular
brand for decades. That makes sales Source: Refinitiv Eikon, 25/11/19, e = forecast estimate.
regular and reliable.
pond, a radical overhaul has the potential present the most important, Saxenda, is
Diabetes is also an increasingly common to seriously dent profits. growing quickly.
disease. In 1980 there were 108m people
in the world with diabetes, by 2014 that However, we think the group has A dominant market share and attractive
number had risen to 422m. That rise is significant opportunities outside end markets would be enough to attract
linked to increasing wealth in emerging insulin as well, specifically through its investors’ attention on their own,
markets, a trend that looks set to GLP-1 products. but Novo also runs a pretty tight ship
continue long term. operationally. That supports operating
These drugs stimulate the body to margins approaching 45%, and the
However, the pharmaceutical industry’s produce more insulin after eating, group’s net cash position underpins a
come under scrutiny in recent years for reducing the need to inject insulin straight modest 2.5% yield.
the price it charges patients, particularly into the body and the associated chances
in the US where uninsured patients of complications. Sales of this category
can face huge costs. That’s put insulin NOVO NORDISK SHARE PRICE,
of drug have been impressive and Novo’s
firmly in the cross-hairs of the more CHARTS AND RESEARCH
gaining market share as a result. The
radical candidates for the Democratic group’s also developed new obesity
presidential nomination. With 48.7% of treatments, and although sales are low at
sales generated across the
WPP REVENUE LESS PASS-THROUGH COSTS 2018
Turning a corner?
The proceeds of the sales have also key North American market – which being offered an attractive above market
helped cut debt to a more manageable accounted for 35% of first half revenue. dividend today, with potential for a
level, despite the smaller size of the recovery in revenues, and valuation to
business. We see this reduction as Those headwinds are expected to see boost share prices, tomorrow. As is always
absolutely crucial to WPP’s long earnings per share fall again this year, and the case though, and especially with
term prospects. the shares are trading on a P/E ratio of cyclical businesses, shares will rise and fall
10.2, significantly below their long term in value and no dividend is guaranteed.
When the economy takes a turn for the average. However, with a lot of the heavy
worse marketing budgets are among the lifting already done, we feel the group
first in the firing line, and a group laden WPP SHARE PRICE,
could be approaching a turning point.
with debt will struggle. The increasing CHARTS AND RESEARCH
The dividend, which currently represents
clout of Alphabet and Facebook is a prospective yield of 6.1%, is comfortably
transforming the sector and adds to covered by earnings and strong cash
uncertainty. More recently the group generation. In that case investors are
has struggled with client losses in the
BUY SHARES
IN 3 SIMPLE STEPS
Ready to start buying shares?
The good news is that it’s much easier than you might
think. If you don’t have a share dealing account, you
could open one online today in minutes.
Then: